• Cancel
    Date：2019-09

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2019-07

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2019-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=425

    The world leader in tumor immunotherapy—Oncologie—has just received USD80 million through its series B financing round. The round was led by Nan Fung Life Sciences and Pivotal BioVentures China. Follow investors included Panacea Ventures, Hualing Capital, Zheshang Industrial Integration Holdings, Jiuyou Fund, Volcanics Ventures, Korea Investment Partners and KB Investment. CEC Capital served as the chief financial adviser to Oncologie during this round of financing.

  • Cancel
    Date：2019-05

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2019-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=419

    Tencent Trusted Doctor Group (hereinafter referred to as “Tencent Trusted Doctor”), the largest non-public medical service platform in China, has raised $250 million in its most recent fundraising round. This round of financing was jointly led by Country Garden Holdings, Tencent, and GAW Capital. Follow investors included CMB International, Harvest Wealth, Russia-China Investment Fund, Sequoia China, SenseGain, and AVIC Trust. This was the first round of investment since the merger between Tencent Doctorwork and Trusted Doctors in 2018. CEC Capital acted as the sole financial adviser to Tencent Trusted Doctor for this round of financing.

  • Cancel
    Date：2019-04

    CEC Capital Served as Exclusive Financial Advisor

  • Cancel
    Date：2019-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=416

    On March 8, WM Motor Technology announced the completion of its C round of financing, securing a total of RMB3 billion. The lead investor was Baidu Inc and the follow investors included Taihang Industrial Fund and Linear Venture. The capital secured durin

  • Cancel
    Date：2019-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=413

    China’s leading therapeutic antibody R&D company, SinoMab Bioscience Limited (“SinoMab”) just completed a Pre-IPO round of financing, securing some hundreds of millions in RMB. This round of investment was co-led by Zhongjin Zhide Equity Investment Management (an investment arm of China International Capital Corporation Limited) and Apricot Capital. SinoMab also announced that it will begin work on its IPO. CEC Capital served as the sole financial adviser to SinoMab during this round of financing.

  • Cancel
    Date：2019-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=411

    Taicang, Suzhou, January 2, 2019/PRNewswire / - Connect Biopharmaceuticals, a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and inflammation, today announces the completion of a $55 mil